AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. NXTC
  4. [S-3] NextCure, Inc. Shelf Registration Statement

[S-3] NextCure, Inc. Shelf Registration Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-3

Filing content is currently unavailable.

Source:

Stock NXTC logo
Nextcure

NASDAQ:NXTC

NXTC Rankings

#5919 Ranked by Market Cap
N/A Ranked by Dividends

NXTC Latest News

Sep 4, 2025
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 7, 2025
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
Jul 24, 2025
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
Jun 16, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
May 29, 2025
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NXTC Latest SEC Filings

Aug 25, 2025
[8-K] NextCure, Inc. Reports Material Event
Aug 19, 2025
[SCHEDULE 13G] NextCure, Inc. SEC Filing
Aug 19, 2025
[Form 3] NextCure, Inc. Initial Statement of Beneficial Ownership
Aug 7, 2025
[10-Q] NextCure, Inc. Quarterly Earnings Report
Jul 14, 2025
[8-K] NextCure, Inc. Reports Material Event

NXTC Stock Data

13.46M
2.28M
14.79%
32.58%
3.29%
Biotechnology
Pharmaceutical Preparations
United States
BELTSVILLE